{"filings":[{"id":787476,"accession_number":"0001104659-26-069206","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2026-06-02T11:05:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rezolute reports positive interim Phase 3 upLIFT data: 6 of 8 patients met primary endpoint","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["8 patients enrolled (50% of planned 16); 6 responders with ≥50% reduction in IV glucose, all 6 achieved complete discontinuation.","One patient withdrew due to cancer progression (Stage 4 colon cancer) counted as non-responder; one patient recently enrolled and dosing.","No drug-related adverse events; all completing pivotal phase entered open-label extension, cumulative treatment up to 6 months.","Topline results for fully enrolled study expected in second half of 2026.","Data supports ersodetug as potential universal treatment for refractory hypoglycemia from congenital and acquired hyperinsulinism."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40443,"accession_number":"0001104659-26-059392","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2026-05-12T20:10:53+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rezolute Q3 FY2026 net loss $16.2M, cash $120.3M; Phase 3 sunRIZE shows >50% hypoglycemia reduction","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $16.2M vs $18.9M YoY; R&D expense $11.4M, down from $15.3M.","Cash and investments $120.3M at Mar 31, 2026, down from $167.9M at Jun 30, 2025.","Phase 3 sunRIZE: ersodetug reduced time in hypoglycemia by >50% (FAS) and 60-80% (PPS) vs placebo.","FDA Type B meeting in March 2026 acknowledged congenital HI challenges; Rezolute to submit comprehensive datasets.","Tumor HI Phase 3 upLIFT trial enrolling; topline results expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93285,"accession_number":"0001104659-26-054943","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rezolute sunRIZE Phase 3 misses primary endpoint; CGM analyses show nominal hypoglycemia reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint (hypoglycemia events by SMBG) not met; secondary CGM endpoint not statistically significant at Week 24/EOT.","CGM analyses showed nominal significance: >50% reduction in time-in-hypoglycemia (FAS), ~60-80% (PPS) vs placebo across timepoints.","OLE: all 59 completers enrolled, 57 continue; up to 24 months exposure; reduced background SOC, many on ersodetug monotherapy.","FDA Type B meeting (Mar 17, 2026) acknowledged primary endpoint challenges; requested comprehensive data submission to inform next steps.","Company believes data show target engagement and therapeutic potential; seeking alignment with FDA on path to approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104777,"accession_number":"0001104659-26-033592","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rezolute provides FDA meeting update after Phase 3 HI trial missed primary endpoint","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["sunRIZE Phase 3 ersodetug trial missed primary endpoint (SMBG hypoglycemia reduction); FDA acknowledged behavioral confounders.","FDA encouraged submission of study reports and analysis datasets for independent evaluation; company expects update in H2 2026.","Preliminary open-label extension data show continued glycemic improvement and reduction of background therapies.","Company believes FDA did not dismiss program; outcomes to be presented at upcoming scientific conference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104776,"accession_number":"0001104659-26-014287","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rezolute Q2 net loss $22.8M; Phase 3 congenital HI study misses primary endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $22.8M vs $15.7M YoY; R&D $14.3M, G&A $9.9M; cash $132.9M down from $167.9M.","Phase 3 sunRIZE study of ersodetug for congenital HI did not meet primary or key secondary endpoints.","Reduction in hypoglycemia by CGM was statistically significant at Week 16 but not at Week 24 endpoint.","FDA meeting planned under Breakthrough Therapy designation before end of Q1 to discuss next steps.","Enrollment ongoing for tumor HI Phase 3 upLIFT study; topline results expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104775,"accession_number":"0001104659-26-001556","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rezolute Phase 3 sunRIZE congenital HI misses endpoints; tumor HI EAP shows 75% IV dextrose discontinuation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 sunRIZE in congenital HI missed primary (hypoglycemia events) and key secondary endpoints; company cites strong placebo response and monitoring effect.","All 59 sunRIZE completers enrolled in open-label extension; 57 remain on ersodetug, durations up to ~18 months; some discontinued all other therapies.","Expanded Access Program in tumor HI: 6 of 8 (75%) patients on IV dextrose/TPN achieved complete discontinuation; 7 of 9 achieved 100% GIR reduction by 8 weeks.","Company plans to meet with FDA in Q1 2026 under Breakthrough Therapy to discuss congenital HI path forward.","Topline results from single-arm Phase 3 upLIFT study in tumor HI expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121052,"accession_number":"0001104659-25-115050","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Rezolute annual meeting: directors elected, equity plan approved, say-on-pay passes with 32% against","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 7 director nominees elected: Kim 52.98M for, Kreher 45.49M for (13.88M withheld), Hogenhuis 45.75M for.","Say-on-pay passed with 40.15M for vs 19.19M against (32% of votes excluding broker non-votes opposed).","Equity plan amendment approved, increasing shares from 14.45M to 21.95M; 59.08M for, 0.26M against.","Ratification of Grant Thornton LLP as auditor passed with 65.21M for, 0.94M against.","Adjournment proposal approved with 57.91M for, 1.42M against to solicit more proxies if needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121051,"accession_number":"0001104659-25-109559","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rezolute hosts investor event on Ersodetug program; no specific data disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company held investor event on November 10, 2025, to update Ersodetug development program.","Presentation filed as Exhibit 99.1 contains no numerical or clinical data in provided text.","Forward-looking statements caution regarding actual results differing from expectations.","No material financial or regulatory changes disclosed in the 8-K or exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121050,"accession_number":"0001104659-25-107743","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rezolute reports Q1 FY2026 net loss $18.2M; Phase 3 sunRIZE topline due Dec 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash & marketable securities $152.2M as of Sep 30, 2025, down from $167.9M on Jun 30.","Net loss $18.2M for Q1 FY2026 vs $15.4M a year ago; R&D $13.1M, G&A $6.7M.","Phase 3 sunRIZE (congenital HI) topline results expected December 2025; registrational alignment with FDA.","Streamlined single-arm Phase 3 upLIFT (tumor HI) enrollment underway; topline data H2 2026.","Virtual investor event Nov 10, 2025 featuring KOLs on commercial opportunity for ersodetug."],"consensus_eps_estimate":-0.1825,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121049,"accession_number":"0001104659-25-101282","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["1.01","5.02","1.02"],"status":"ready","headline":"Rezolute amends exec employment agreements for 280G gross-up; terminates unused Jefferies ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Nevan Elam, CMO Brian Roberts, CFO Daron Evans, CCO Sunil Karnawat get full gross-up for 280G excise tax on change-of-control payments.","Gross-up amount determined by Company in its sole discretion; other terms of employment agreements unchanged.","Company terminated Open Market Sale Agreement with Jefferies LLC effective Oct 24, 2025; no sales were made under the ATM program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137684,"accession_number":"0001104659-25-090834","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rezolute reports FY2025 net loss $74.4M; sunRIZE topline Dec 2025, FDA streamlines tumor HI trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.4M for Q4 FY2025, $74.4M full year; cash $167.9M as of June 30, 2025 (up from $127.1M).","Phase 3 sunRIZE (congenital HI) fully enrolled with 62 participants; topline results expected December 2025.","FDA aligned on streamlined Phase 3 upLIFT (tumor HI) with as few as 16 participants; topline H2 2026.","Appointed Dr. Sunil Karnawat as Chief Commercial Officer in August 2025 to lead launch strategy.","R&D expenses $61.5M (FY2025) vs $55.7M; G&A $18.4M vs $14.7M; increases driven by trial and headcount."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137683,"accession_number":"0001104659-25-085892","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rezolute gains FDA alignment on streamlined Phase 3 trial design for ersodetug in tumor HI","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agreed to remove double-blind placebo-controlled requirement; study now open-label, single-arm.","Phase 3 upLIFT trial will enroll as few as 16 patients with tumor hyperinsulinism (HI).","Topline data from upLIFT expected in the second half of 2026.","FDA confirmed that the pivotal sunRIZE trial in congenital HI (topline Dec 2025) serves as confirmatory evidence.","FDA meeting held August 19, 2025; simplified path based on Expanded Access Program outcomes in over 10 patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137682,"accession_number":"0001104659-25-080473","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Rezolute appoints Sunil Karnawat as CCO; grants 275K inducement options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sunil Karnawat appointed Chief Commercial Officer effective Aug 18, 2025; brings 25+ years experience including four ultra-rare disease launches at Ultragenyx.","Employment agreement: base salary $475K, annual target bonus 40%, signing bonus $65K, plus 270K stock options and 25K RSUs vesting over time.","Inducement grant of 275K stock options at $6.55/share (closing price Aug 18); vesting: 25% on first anniversary, then 36 monthly installments, accelerated upon change of control.","Karnawat will lead launch strategy and global market readiness for ersodetug, a Phase 3 therapy for congenital and tumor hyperinsulinism."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137681,"accession_number":"0001104659-25-068804","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rezolute fully enrolls Phase 3 sunRIZE study of ersodetug; topline data expected by end of 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["63 participants enrolled (8 open-label infants, 55 double-blind); DMC recommended continuing with original sample size after interim analysis.","Baseline hypoglycemia burden severe: mean 15 events/week (SMBG), 19% time <70 mg/dL (CGM); 51% hospitalized in past year.","76% of participants have kATP channel mutations (typically diazoxide non-responsive); 19% on 2+ medical therapies, 40% on enteral feeding.","29% experienced severe hypoglycemia with loss of consciousness requiring emergency intervention in past year.","Topline safety and efficacy results from pivotal 24-week treatment period anticipated by end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155061,"accession_number":"0001104659-25-059336","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Rezolute closes $4.2M private placement with insiders at $3.25/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 1,295,383 shares for aggregate proceeds of $4,209,994.75 to insiders on June 13, 2025.","Price per share was $3.25, consistent with the previously announced up-to-$10M private placement from April 23, 2025.","Shares issued in reliance on Section 4(a)(2) exemption from registration; no underwriter or public offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155056,"accession_number":"0001104659-25-059340","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K/A","filed_at":"2025-06-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Rezolute appoints Erik Harris to Compensation Committee, effective July 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Erik Harris, appointed to Board on March 25, 2025, added to Compensation Committee effective July 1, 2025.","Committee assignment completes prior disclosure; no other committee changes reported.","Filing amends initial 8-K to supplement director committee information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155060,"accession_number":"0001104659-25-047832","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rezolute Q3 net loss $18.9M; sunRIZE enrollment on track, BTD for ersodetug","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $88.4M at March 31, 2025, down from $127.1M at June 30, 2024.","Phase 3 sunRIZE study enrollment expected to complete May 2025; topline results anticipated December 2025.","FDA granted Breakthrough Therapy Designation to ersodetug for tumor hyperinsulinism hypoglycemia in May 2025.","April 2025 underwritten offering raised ~$97M, extending cash runway to mid-2027.","Appointed Erik Harris (Ultragenyx CCO) to Board of Directors in March 2025."],"consensus_eps_estimate":-0.2703,"consensus_eps_actual":-0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155059,"accession_number":"0001104659-25-040271","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rezolute closes $96.9M equity offering at $3.25/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aggregate of 24,940,769 common shares at $3.25 plus 6,905,385 pre-funded warrants at $3.2490 each.","Net proceeds of approx. $96.9 million; intended for R&D, corporate expenses, and working capital.","Underwriters' option to purchase additional shares exercised in full.","Separate private placement of $4.2M shares at same price; expected close May 7, 2025.","Participation from Federated Hermes, Blackstone, Great Point Partners, Marshall Wace, and others."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155058,"accession_number":"0001104659-25-038096","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["1.01","3.02","8.01","7.01","9.01"],"status":"ready","headline":"Rezolute prices $90M registered direct offering of common stock and pre-funded warrants at $3.25/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced underwritten offering of 20.8M shares and 6.9M pre-funded warrants for gross proceeds of ~$90M; net proceeds ~$84.2M.","Insiders to purchase up to $10M of common stock in concurrent private placement at same $3.25 price.","Underwriters granted 30-day option for additional 4.15M shares; closing expected April 24, 2025.","Participants include Federated Hermes, Blackstone, Great Point Partners, Marshall Wace, Woodline, and others.","Proceeds to fund R&D and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155057,"accession_number":"0001104659-25-037746","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rezolute's Phase 3 sunRIZE study of ersodetug gets positive DMC recommendation; enrollment May, data Dec 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Independent DMC recommends continuation of sunRIZE study as planned; no need to increase sample size.","Enrollment expected to complete in May 2025; topline data anticipated in December 2025.","U.S. sites now activated and enrolling; global study across more than a dozen countries.","Interim analysis evaluated primary endpoint of hypoglycemia events after ~50% of patients completed assessments.","Rezolute remains blinded to interim data; DMC recommendation based on pre-specified futility and sample size assessment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173584,"accession_number":"0001104659-25-029429","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Rezolute appoints Erik Harris to board of directors effective March 25, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Erik Harris elected to board effective March 25, 2025; determined independent under Nasdaq rules.","Harris is CCO and EVP at Ultragenyx Pharmaceutical since June 2019; previously VP at InterMune, Crescendo Bioscience.","Will receive standard non-employee director cash retainer (pro-rated) and 60,000 stock options at $2.89 exercise price.","Options vest monthly from March 25, 2025, expiring March 25, 2035; committee assignments pending.","No family relationships with directors/officers and no material interest in transactions required to disclose."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173583,"accession_number":"0001104659-25-012173","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rezolute reports Q2 net loss $15.7M; ersodetug gets Breakthrough Therapy, Orphan Drug status","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash & equivalents $105.3M at Dec 31, 2024 vs $127.1M at June 30, 2024.","Net loss $15.7M for Q2 fiscal 2025 vs $13.9M for same period last year.","FDA granted Breakthrough Therapy Designation for ersodetug in congenital hyperinsulinism (HI).","FDA granted Orphan Drug Designation for ersodetug in tumor HI.","Phase 3 sunRIZE study interim analysis planned this quarter; topline results expected Q4 2025."],"consensus_eps_estimate":-0.2244,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173582,"accession_number":"0001104659-25-009180","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rezolute DMC clears ersodetug open-label arm in infants; interim analysis expected Q1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DMC reviewed 8 infants (3mo-1yr) on 5/10 mg/kg bi-weekly/monthly: safe, target concentrations reached.","Infants may now enroll in double-blind placebo-controlled portion of sunRIZE Phase 3 study.","Enrollment completion expected Q2 2025 pending interim analysis; topline results Q4 2025 if no change.","Interim analysis end of Q1 2025; three outcomes: futility, continue as is, or increase sample size by 33% (18 pts).","If sample size increased, enrollment shifts to Q4 2025, topline results to mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173581,"accession_number":"0001104659-25-003460","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rezolute shares patient testimonial with favorable results for ersodetug in Phase 2 study","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Company released a pre-recorded video detailing a patient's experience in the Phase 2 trial of investigational drug ersodetug.","Video notes favorable results for that single patient but cautions they may not be representative of broader trial outcomes.","Ersodetug is not FDA-approved; no safety or efficacy determination has been made by the agency.","Transcript filed as Exhibit 99.1 includes forward-looking statements and risk factors.","No new quantitative clinical data or regulatory milestones disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173580,"accession_number":"0001104659-25-001666","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rezolute (RZLT) gets FDA Breakthrough Therapy Designation for ersodetug in congenital hyperinsulinism","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Breakthrough Therapy Designation to ersodetug (RZ358) for hypoglycemia due to congenital hyperinsulinism.","Designation based on Phase 2b (RIZE) study: ≥75% reduction in hypoglycemia, no clinically significant hyperglycemia.","Topline results from Phase 3 sunRIZE study expected H2 2025; U.S. sites enrolling after partial clinical hold lifted.","Company raised $73M in June 2024, extending cash runway into Q2 2026 to support clinical programs.","Also received ODD and IND clearance for tumor HI Phase 3 study, with topline results expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190562,"accession_number":"0001104659-24-127228","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Rezolute shareholders approve increase in authorized common stock to 165M shares and equity plan amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased from 100M to 165M shares via Certificate of Amendment filed Dec 6, 2024.","Proposal passed with 36,449,851 votes for; 134,695 against; 3,496 abstentions.","2021 Stock Incentive Plan reserve increased from 10.7M to 14.45M shares (31,485,706 for; 5,094,003 against).","All six director nominees elected; Grant Thornton ratified as auditor for FY2025.","Say-on-pay advisory vote passed with 36,519,454 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190561,"accession_number":"0001104659-24-115351","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rezolute Q1 FY2025 net loss $15.4M; cash $117.8M; Phase 3 on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $15.4M vs $14.5M YoY; R&D $12.8M, G&A $4.2M.","Cash, equivalents, marketable securities $117.8M (Sep 30) vs $127.1M (Jun 30).","Phase 3 sunRIZE congenital HI enrollment on track; U.S. enrollment expected early 2025.","Tumor HI Phase 3 enrollment expected H1 2025; topline results H2 2026.","Topline sunRIZE results expected in second half of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207055,"accession_number":"0001104659-24-101342","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2024-09-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rezolute reports Q4 FY2024 net loss of $23M; FDA lifts partial clinical hold on ersodetug","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $23.0M vs $12.7M prior year; full year net loss $68.5M vs $51.8M.","Cash and investments $127.1M at June 30, 2024, up from $118.4M year-over-year.","FDA lifts partial clinical holds on ersodetug for congenital HI; U.S. enrollment in Phase 3 sunRIZE expected early 2025.","Phase 3 study for tumor HI to begin H1 2025; topline results expected mid-2026.","Phase 2 RZ402 for DME met primary endpoints; partnering discussions ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207054,"accession_number":"0001104659-24-097969","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA lifts partial clinical holds on Rezolute's RZ358 for congenital hyperinsulinism","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA removed partial clinical holds on RZ358 (ersodetug) for hypoglycemia in congenital HI; U.S. enrollment in global Phase 3 sunRIZE study now permitted.","FDA concluded liver toxicity in Sprague Dawley rats is strain-specific and not relevant to humans.","Company expects to begin U.S. participant enrollment in early 2025; topline data from sunRIZE study anticipated in H2 2025.","This follows prior FDA clearance of a separate Phase 3 study in tumor-associated HI, advancing ersodetug in two rare disease programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207053,"accession_number":"0001104659-24-085614","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rezolute receives FDA IND clearance for Phase 3 study of RZ358 in tumor hyperinsulinism","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for RZ358 (ersodetug) Phase 3 registrational trial treating hypoglycemia due to tumor HI.","Double-blind, placebo-controlled study of 24 participants; enrollment expected to start H1 2025.","Ongoing Phase 3 for congenital HI; topline data anticipated mid-2025.","Drug is a fully human monoclonal antibody binding to insulin receptor allosteric site.","Prior Expanded Access Program showed real-world benefit in tumor HI patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224370,"accession_number":"0001104659-24-076382","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rezolute releases Phase 2 topline results for RZ402 in DME; no specifics in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Topline results from Phase 2 study of RZ402 in diabetic macular edema (DME) disclosed via website and SEC filing on June 28, 2024.","Presentation originally provided during May 21, 2024 investor webcast; appendix added on June 28, 2024.","Actual efficacy or safety data (e.g., p-values, responder rates) are not visible in the available 8-K or exhibit text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224369,"accession_number":"0001104659-24-075387","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Rezolute raises ~$67M through public offering and concurrent private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriters exercised over-allotment option for 1,786,589 shares at $4.00 each.","Total offering: 13,036,589 shares plus pre-funded warrants for 3.75M shares; gross proceeds ~$67M.","Concurrent private placement of 1.5M shares at $4.00/share for ~$6M in additional gross proceeds.","Net proceeds will fund clinical R&D (RZ358 for hyperinsulinism) and working capital.","Jefferies and Cantor acted as joint book-running managers for the public offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224368,"accession_number":"0001104659-24-071813","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Rezolute prices $60M public offering of 11.25M shares and pre-funded warrants at $4.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering includes 11,250,000 shares of common stock at $4.00/share and pre-funded warrants for 3,750,000 shares at $3.999 each.","Expected net proceeds of approximately $56M (or $64.5M if underwriters' option is fully exercised).","Proceeds to fund R&D and general corporate purposes; closing expected on or about June 17, 2024.","Jefferies and Cantor Fitzgerald act as joint book-running managers; underwriters have 30-day option for additional 2.25M shares.","Lock-up agreements with officers, directors, and certain stockholders for 90 days post-offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224367,"accession_number":"0001104659-24-065073","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rezolute reports positive Phase 2 results for RZ402 in DME; CST reduced up to ~50 microns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 study of 94 DME patients met primary endpoints: CST reduction (p=0.02) and good safety profile.","CST improvement up to ~50 microns; 200 mg dose showed largest response; sub-analysis at CST ≥400 showed ~75 micron improvement.","RZ402 safe and well-tolerated; AEs mild and comparable to placebo; no ocular adverse effects typical of intravitreal injections.","No significant BCVA improvement, consistent with study duration; five 200 mg patients (20%) had 1-step DRSS improvement.","Target concentrations exceeded at all three doses (50, 200, 400 mg) supporting once-daily oral dosing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224366,"accession_number":"0001104659-24-063029","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Rezolute stockholders approve all proposals at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected with >26.8M votes each: Kim, Elam, Fauchet, Labrucherie, Hogenhuis, Kreher.","Ratification of Grant Thornton as independent auditor approved: 27.35M for, 3,686 against.","Say-on-pay advisory vote approved: 26.68M for, 225,756 against.","Equity plan amendment to add incentive compensation recovery policy approved: 26.55M for, 338,688 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224365,"accession_number":"0001104659-24-061933","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rezolute reports Q3 FY2024 net loss $17.1M; sunRIZE Phase 3 enrolling, DME Phase 2 topline expected May 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $17.1M for Q3 FY2024 vs $15.7M YoY; cash and equivalents $81.6M (down from $118.4M in June 2023).","sunRIZE Phase 3 for cHI (RZ358) enrolling; completion expected end-2024; topline data mid-2025.","Completed in-vivo tox study in brown Norway rats at 40 mg/kg; no liver abnormalities; to submit to FDA summer 2024.","DME Phase 2 (RZ402) completed dosing of 94 patients; topline results expected May 2024.","FDA alignment for potential registrational study in tumor HI; 5 insulinoma patients treated under Expanded Access."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224364,"accession_number":"0001104659-24-052074","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rezolute to present Phase 2 RIZE overnight hypoglycemia data at PES Annual Meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Paul Thornton will present poster analyzing overnight hypoglycemia in congenital HI patients on May 4, 2024 at PES meeting.","Sub-analyses from Phase 2 RIZE study highlight RZ358 benefits during overnight fasting using CGM metrics.","Previously reported results showed up to ~90% reduction in hypoglycemia events and time at top doses.","Phase 3 study of RZ358 for congenital hyperinsulinism is currently underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243684,"accession_number":"0001104659-24-034564","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["1.01","4.01","9.01"],"status":"ready","headline":"Rezolute exchanges 3M common shares for pre-funded warrants; reduces outstanding by 3M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged 3,000,000 shares with certain stockholders for pre-funded warrants exercisable at $0.001/share.","Retired shares cancelled, reducing outstanding common stock by 3,000,000 shares; company paid $3,000 total.","Warrants not exercisable if holder would own >9.99% after exercise; also subject to 19.99% limit pending stockholder approval.","Dismissed Plante & Moran as auditor, appointed Grant Thornton LLP; no disagreements other than prior material weakness disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243683,"accession_number":"0001104659-24-033068","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rezolute validates RZ358 for NICTH, doubling addressable tumor HI patient population","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preclinical study shows RZ358 blunts IGF-2 and insulin-mediated signaling at clinically relevant levels.","Total addressable US market for tumor HI est. at ~4,500 patients (1,500 ICTH + 3,000 NICTH).","Company evaluating registrational study in tumor HI including both ICTH and NICTH after positive Jan 2024 FDA interaction.","RZ358 already in Phase 3 for congenital HI; has Orphan Drug Designations in US/EU for multiple indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243682,"accession_number":"0001104659-24-026582","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rezolute regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["On Feb 21, 2024, Rezolute received Nasdaq notice of regained compliance with $1.00 Minimum Bid Price requirement.","Compliance achieved by closing bid price above $1.00 for 10 consecutive business days through Feb 20, 2024.","Initial non-compliance notice was from Nov 21, 2023 after stock closed below $1.00 for 30 trading days.","Company's common stock continues trading on Nasdaq Capital Market under ticker RZLT."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243681,"accession_number":"0001104659-24-019884","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rezolute reports Q2 FY2024 net loss $13.9M; initiates Phase 3 for RZ358 in cHI","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.9M for Q2 FY2024, compared to $13.6M same period prior year.","Cash, cash equivalents and investments $96.0M as of Dec 31, 2023, down from $118.4M at June 30, 2023.","Initiated sunRIZE Phase 3 study of RZ358 in congenital hyperinsulinism; topline results expected mid-2025.","Completed enrollment in Phase 2 study of RZ402 for diabetic macular edema; topline data expected Q2 2024.","Appointed Daron Evans as CFO, expanding leadership for late-stage development."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243680,"accession_number":"0001104659-24-007811","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2024-01-29T23:59:59+00:00","items":["3.02","5.02","7.01","9.01"],"status":"ready","headline":"Rezolute appoints Daron Evans as CFO; receives UK Innovation Passport for RZ358","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Daron Evans appointed CFO, effective Jan 23, 2024; base salary $275,000, target bonus 50%.","Received inducement grant of 275,000 stock options at $1.02 (closing price), vesting over 4 years.","UK MHRA awarded Innovation Passport to RZ358 for congenital hyperinsulinism treatment.","Innovation Passport is entry to ILAP, aims to accelerate time to market and patient access.","Phase 3 study for RZ358 initiated; Phase 2 RZ402 data expected Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261082,"accession_number":"0001104659-23-126021","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rezolute completes Phase 2 DME enrollment, initiates Phase 3 for congenital hyperinsulinism","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 study of oral RZ402 for diabetic macular edema enrolled ~95 participants; topline data expected mid-Q2 2024.","Phase 3 sunRIZE study of RZ358 for congenital hyperinsulinism initiated; first clinical site activated outside US.","Phase 3 to enroll up to 56 patients at ~20 centers in >12 countries; topline results anticipated mid-2025.","RZ358 previously received EMA PRIME designation in October 2023 for congenital hyperinsulinism."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261081,"accession_number":"0001104659-23-120789","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2023-11-22T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Rezolute receives Nasdaq delisting notice for bid price below $1.00; has until May 20, 2024 to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice on Nov 21, 2023: closing bid below $1.00 for 30 consecutive trading days.","Company has 180 days (until May 20, 2024) to regain compliance by having bid ≥$1.00 for 10 consecutive days.","If not in compliance by May 20, 2024, may qualify for additional 180-day grace period if other listing requirements are met.","Company is evaluating options but cannot assure compliance will be achieved.","Delisting would materially and adversely affect Rezolute's ability to raise capital and its financial condition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261080,"accession_number":"0001104659-23-117219","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rezolute Q1 FY2024 net loss $14.5M; RZ358 Phase 3 start planned before year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.5M for Q1 FY2024 vs $9.8M in same period last year.","R&D expenses $12.2M (up 58% YoY) due to increased clinical and manufacturing costs.","Cash and investments $106.9M as of Sep 30, 2023, down from $118.4M at Jun 30, 2023.","RZ358 granted EMA PRIME designation; Phase 3 sunRIZE study for congenital hyperinsulinism to initiate Q4 2023.","RZ402 Phase 2 enrollment in diabetic macular edema near completion; update expected before year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261079,"accession_number":"0001104659-23-109878","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2023-10-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rezolute receives EMA PRIME eligibility for RZ358 in congenital hyperinsulinism","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["EMA grants PRIME eligibility to RZ358 for congenital HI, citing unmet medical need and positive Phase 2b data.","PRIME provides enhanced regulatory support to accelerate development and evaluation.","Phase 3 study for RZ358 planned to initiate in Q4 2023.","Phase 2b RIZE study showed ~75% average improvement in hypoglycemia at intended Phase 3 doses.","Improvement was consistent across age groups (2-6, 6-12, >12 years)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261078,"accession_number":"0001104659-23-109133","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2023-10-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rezolute reports RZ358 resolves hypoglycemia in tumor-mediated hyperinsulinism patient","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RZ358 administered on compassionate-use basis to patient with refractory hypoglycemia due to metastatic insulin-secreting cervical cancer.","Treatment started September 2023; resulted in resolution of hypoglycemia and enabled hospital discharge to resume cancer therapy.","Prior metastatic insulinoma patient has remained on RZ358 for nearly a year; case published in NEJM (389;8).","Company sees RZ358 as potential universal treatment for hyperinsulinism; evaluating next steps in additional indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278359,"accession_number":"0001104659-23-100787","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2023-09-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rezolute reports FY2023 net loss of $51.8M; Phase 3 for RZ358 to start Q4 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $16.0M, marketable securities $102.3M as of June 30, 2023.","Full year net loss $51.8M vs $41.1M prior year; R&D spend $43.8M (up from $32.5M).","Phase 3 sunRIZE study for RZ358 in congenital HI to initiate Q4 2023; topline data H1 2025.","Phase 2 study of RZ402 for diabetic macular edema ongoing; results expected Q1 2024.","Q4 net loss $12.7M vs $9.4M in prior year quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296499,"accession_number":"0001104659-23-075241","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2023-06-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Rezolute to initiate Phase 3 for RZ358 in congenital HI outside US in Q4 2023; FDA restrictions prevent US inclusion","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Phase 3 sunRIZE study of RZ358 planned in Europe/ex-US starting Q4 2023; topline results expected 1H 2025.","FDA maintained age restriction (12+ years) and re-imposed dose cap based on rat toxicology; US inclusion currently infeasible.","Company evaluating nonclinical studies to address FDA concerns in parallel with ex-US Phase 3; cash $129M sustains ops through Q3 2025.","Phase 2b RIZE study showed RZ358 generally safe, well-tolerated, and effective in improving hypoglycemia.","Estimated congenital HI prevalence >10,000 in primary markets; >50% lack adequate treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296498,"accession_number":"0001104659-23-072543","cik":1509261,"company_name":"Rezolute, Inc.","ticker":"RZLT","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Rezolute reports first use of RZ358 for insulinoma; patient achieved substantial hypoglycemia benefit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Patient with metastatic insulinoma and intractable hypoglycemia received RZ358 under compassionate use IND.","Treatment began Q4 2022; patient continues therapy with substantial benefit and improved quality of life per Dr. Patti.","Case presented as late-breaking abstract at ENDO 2023 on June 16, 2023; abstract published in Journal of Endocrine Society.","This marks the first time Rezolute's RZ358 has been used for insulinoma indication."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":313431520.81626505,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-06-20T23:59:59+00:00|296498"}